{"version":"1.0","description":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial\uff08Lancet Oncol 2022, Published OnlineSeptember 12, 2022\uff09 \u307e\u3068\u3081 \u30b9\u30c6\u30fc\u30b8IB-IIIA\u671f\u306e\u5b8c\u5168\u5207\u9664\u5f8c\u30a2\u30b8\u30e5\u30d0\u30f3\u30c8\u3068\u3057\u3066\u306e\u307a\u30e0\u30d6\u30ed\u30ea\u30ba\u30de\u30d6\u306f\u7121\u75c5\u751f\u2026","blog_url":"https://lk.hatenablog.jp/","height":"190","published":"2022-09-26 06:00:00","categories":["\u6cbb\u7642 \u514d\u75ab\u7642\u6cd5","\u80ba\u764c\u306e\u57fa\u790e","\u6cbb\u7642 \u624b\u8853\u7642\u6cd5","\u6cbb\u7642 \u5468\u8853\u671f"],"url":"https://lk.hatenablog.jp/entry/2022/09/26/060000","author_url":"https://blog.hatena.ne.jp/lung-cancer/","author_name":"lung-cancer","blog_title":"\u30ad\u30e5\u30fc\u30c8\u5148\u751f\u306e\u300e\u80ba\u764c\u52c9\u5f37\u4f1a\u300f","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Flk.hatenablog.jp%2Fentry%2F2022%2F09%2F26%2F060000\" title=\"\u3010PEARLS/KENOTE-091\u3011 \u5b8c\u5168\u5207\u9664\u5f8c\u306e\u307a\u30e0\u30d6\u30ed\u30ea\u30ba\u30de\u30d6\u306f\u6709\u610f\u306b\u7121\u75c5\u751f\u5b58\u671f\u9593\u3092\u5ef6\u9577 - \u30ad\u30e5\u30fc\u30c8\u5148\u751f\u306e\u300e\u80ba\u764c\u52c9\u5f37\u4f1a\u300f\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","type":"rich","title":"\u3010PEARLS/KENOTE-091\u3011 \u5b8c\u5168\u5207\u9664\u5f8c\u306e\u307a\u30e0\u30d6\u30ed\u30ea\u30ba\u30de\u30d6\u306f\u6709\u610f\u306b\u7121\u75c5\u751f\u5b58\u671f\u9593\u3092\u5ef6\u9577","provider_name":"Hatena Blog","image_url":"https://cdn-ak.f.st-hatena.com/images/fotolife/l/lung-cancer/20220926/20220926073543.png","width":"100%","provider_url":"https://hatena.blog"}